Allyx Therapeutics is a clinical-stage biotechnology company developing regenerative medicine therapies aimed at restoring neuronal function in patients with neurodegenerative diseases. Their approach focuses on enhancing cognitive health by targeting the underlying mechanisms of neurodegeneration.

Artizan Biosciences specializes in drug discovery and development targeting diseases linked to the human intestinal microbiota through advanced microbiome analysis and therapeutic interventions. The company aims to improve patient outcomes by developing precise treatments that restore microbial balance and enhance gut health.

Arvinas uses a proprietary PROTAC discovery engine to design bifunctional molecules that recruit E3 ubiquitin ligases and trigger proteasomal degradation of disease‑relevant proteins, expanding the druggable proteome for oncology and neurodegenerative indications. The company advances clinical‑stage degraders and offers partnership models for pharmaceutical and biotechnology companies to co‑develop or license these targeted protein‑degradation therapeutics.

AtlasXomics provides a spatial epigenome mapping solution at the single-cell level using the FlowGel220 kit, enabling precise analysis of gene regulation in oncology, neurology, and aging research. This technology addresses the need for high-resolution spatial context in epigenomic studies, facilitating a deeper understanding of cellular behavior and disease mechanisms.

Axiom provides a cloud-native log management platform that enables high-scale engineering teams to collect, store, and analyze event data in real-time without limits. By offering a cost-effective solution with up to 92.5% savings on logging expenses, Axiom empowers organizations to maximize the value of their log data while simplifying data management and governance.

CellFE develops a microfluidics-based device that delivers gene-editing molecules to enhance cell health and yield during the manufacturing of cell therapies. This technology addresses the challenges of long production times and high costs, enabling scalable and efficient processes from research to commercial applications.

Cera is a platform enabling global users to invest in US stocks directly using stablecoins like USDC and USDT. Users deposit stablecoins which are immediately converted 1:1 to USD cash for trading fractional shares of supported tickers. This service removes geographical barriers and simplifies the process of accessing US equity markets through digital currency integration.

Cybrexa Therapeutics is developing a novel class of peptide-drug conjugates (PDCs) utilizing its proprietary alphalex™ technology to deliver potent anti-cancer agents directly into tumor cells, bypassing the need for antigen targeting. This approach addresses the challenge of effectively treating various solid tumors, including those resistant to conventional therapies, by enhancing drug delivery while minimizing toxicity to healthy tissues.

Demos develops AI-driven music production tools that generate infinite, unique audio samples, including loops and one-shots, to enhance the creative process for music producers. By streamlining the transition from inspiration to polished production, Demos addresses the challenge of limited sample availability in music creation.

Enrich Biosystems provides the TROVO benchtop instrument for high-throughput functional screening and live-cell retrieval in a fluidics-free system. This platform enables researchers to 3D print hydrogel microwells within standard microplates for long-term imaging of micro-cultures. The system uses AI-enabled tools for analysis, allowing for the selection and retrieval of functional cells based on observed cellular kinetics.

EvolveImmune develops novel cancer immunotherapies using its proprietary EVOLVE platform to create trispecific T cell engagers with integrated CD2 costimulation. This approach is designed to overcome resistance mechanisms seen with existing immunotherapies. The company is advancing its lead candidate, EVOLVE104, into clinical trials for solid tumors.

Develops RIPTAC™ therapeutics, a novel class of precision cancer treatments that use a protein-protein interaction mechanism to selectively bind tumor-specific proteins and essential cellular functions, leading to targeted cancer cell death. This approach addresses the limitations of traditional therapies by offering a more precise and effective method for treating major solid tumors.

Icon provides an all-in-one communication and engagement software designed specifically for organizations that support seniors, utilizing advanced messaging and engagement tools to enhance interactions between older adults and care providers. The platform addresses the challenge of ensuring effective communication and engagement, improving the overall experience for both seniors and their caregivers.

Ko is a networking platform that organizes educational resources and facilitates the creation of professional profiles for individuals and teams. It addresses the challenge of connecting job seekers with educational opportunities by providing a centralized space for resource sharing and job postings.

Metagenomi utilizes metagenomics and machine learning to discover and develop novel genome editing systems that enable precise modifications to the human genome. This technology addresses the limitations of existing gene editing methods by providing a versatile toolbox capable of targeting specific sites for therapeutic interventions.

Occam provides an AI-powered platform for developers to build and deploy machine learning models efficiently. The service streamlines the MLOps lifecycle, offering tools for data preparation, model training, and scalable inference management. This enables engineering teams to accelerate the transition from prototype to production-ready AI applications.

Om provides access to massive, internally generated datasets detailing proteome-wide small molecule binding data. Researchers can programmatically query billions of protein and small molecule interaction data points to identify therapeutic opportunities instantly. The platform leverages synthetic biology and pico-scale engineering to accelerate the transition from hypothesis to launching a discovery program.

Osmol Therapeutics is developing OSM-0205, an intravenous treatment designed to prevent chemotherapy-induced peripheral neuropathy (CIPN) and cognitive impairment (CICI) by targeting calcium surge interactions that lead to neuronal damage. This approach aims to enhance chemotherapy dosing and improve patient outcomes for those at risk of debilitating side effects from taxane-based therapies.

P2 Science develops sustainable, high-performance liquid polymers from natural pine oil using green chemistry principles, specifically designed to replace petroleum-based emollients in personal care products. This technology addresses the environmental impact of synthetic compounds in the beauty industry by providing eco-friendly alternatives that enhance product performance.

RA UNLIMITED harnesses solar photovoltaic technology to generate clean and affordable electricity for homes, businesses, and communities in the Philippines. The company addresses the reliance on fossil fuels by providing sustainable energy solutions that create jobs and enhance the quality of life for Filipinos.

Rated provides independent ratings and robust data pipelines for validators and node operators in proof-of-stake networks, enabling users to access high-integrity performance metrics. The platform addresses the challenge of fragmented and poorly contextualized Web3 infrastructure data, facilitating informed decision-making for stakers and developers.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Samara installs solar panels for households, enabling users to save an average of €1,092 annually on electricity bills while reducing carbon emissions. The company manages the entire installation process, including financing options and securing subsidies, ensuring a seamless transition to renewable energy.

TAI offers a mobile application that enables users to manage and optimize their investment portfolios through real-time analytics and performance tracking. The platform addresses the challenge of fragmented investment management by providing a unified interface for monitoring asset performance and making informed decisions.